Coronavirus Live Count Map India
remove_red_eye 767 Views
COVID-19 Vaccine Updates
Natural immunity boosters: Clinical trial reports
Due to industrialization and sedentary lifestyle a significant increase in Allergic disorders has been observed in the recent years. Is has been classified as one of the “three major diseases of the 21st century” by the World Health Organization (WHO) and “a public health issue of global concern” by World Allergy Organization (WAO). The white book of WAO discloses that about, 300 million people around the world have experienced asthma, and about 200 to 250 million people developed food allergies.
Allergies, are reactions by the immune system in response to exposure to certain foreign substances which are called as allergens which may include pollens, dust mites, molds, animal proteins, certain metals , foods, and medications. Allergy due to metal, food, medications are mostly both genetic and triggered by environmental factors. Most common allergies include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Common symptoms include red eyes, an itchy rash, sneezing, a runny nose, shortness of breath, or swelling.1
In case of allergic disorders, such as anaphylaxis, hay fever, some food allergies and allergic asthma, IgE and T helper 2 (TH2) cells are involved which identify allergen-derived antigens.2 Hence a study was conducted to evaluate anti-allergic properties of Mulmina®
Study design and Method 3
The study was designed to determine the safety of Mulmina®, hence as one of the parameters the anti-allergic properties of Mulmina® was determined.
The method used were seven well known and important anti-allergic models
- Model 1: Compound 48/80-induced mast cell degranulation in rat mesentery
- Model 2: Compound 48/80-induced mast cell degranulation in rat peritoneal fluid
- Model 3: Milk induced leukocytosis and eosinophilia in mice
- Model 4: Effect of Mulmina® on 48/80-induced systemic anaphylaxis
- Model 5: Effect of Mulmina® on histamine-induced contraction of smooth muscle by using isolated guinea pig tracheal chain preparation
- Model 6: Effect of Mulmina® against histamine-induced bronchospasm in guinea pigs
- Model 7: Anti-allergic effect of Mulmina® in ovalbumin-induced airway hyperresponsiveness in Balb/c mice
The results were tabulated as below
|1||Induced mast cell degranulation in rat mesentery using compound 48/80||Significant reduction in number of degranulated cells with maximum protection was observed after treating with Mulmina®.||The mast cell stabilizing property was Anti-allergic activity of Mulmina® was confirmed by its|
|2||Induced mast cell degranulation in rat peritoneal fluid using compound 48/80||Significant protection of intact cells was observed by treating with Mulmina® showed||The mast cell stabilising property of Mulmina® was Reconfirmed and also justified the antiallergic activity|
|3||Induced leukocytosis and eosinophilia in mice using milk||Significant reduction in antigen-induced immunological reaction, decrease in the leukocytes and eosinophil count was also observed by treating with Mulmina®||Reduction in the elevated levels of leukocytes and eosinophil proved that Mulmina® supplement enhanced the raised immune power|
|4||Effect of Mulmina® on systemic anaphylaxis.||Treatment with higher dose of Mulmina® showed protection against histamine-induced anaphylactic shock/mortality.||Anti-anaphylactic activity by stabilizing the mast cells was observed by treating with Mulmina®. It inhibited the deleterious effect of histamine by blocking the release of histamines from cells.|
|5||To observe the effect of Mulmina® Histamine induced contraction of smooth muscle on isolated guinea pig tracheal chain preparation||90% protection was observed against histamine-induced tracheal smooth muscle contraction by treatment of Mulmina®||Treating with Mulmina® inhibited the airway smooth muscle contraction in allergic condition, which confirmed the Anti-allergic activity of Mulmina®|
|6||Effect of Mulmina® against histamine-induced bronchospasm in guinea pigs||4.5- and 9.0-folds increase in pre-convulsive time was observed by administration two doses of Mulmina® compared to inhalation of histamine alone in a group of guinea pigs.||protection against histamine-induced bronchoconstriction was seen by treating with Mulmina®|
|7||Ovalbumin-induced airway hyperresponsiveness was used to study the anti-allergic effect of Mulmina® in Balb/c mice||A decrease of about 2-4 folds was observed by treating with Mulmina® in the pro-inflammatory cytokines TNF-α, tissue damage marker (LDH), neutrophil infiltration marker (MPO), oxidative stress markers (nitrate and lipid peroxidation) in ovalbumin-induced airway disease||Treatment of Mulmina® proved its anti-allergic activity by reducing inflammatory and oxidative stress in ovalbumin-induced airway respiratory illness|
Discussion 4 ,5, 6
Safety and efficacy of any supplement pays the key role in the acceptance of the product in the market. Eosinophils are circulating and tissue-resident leukocytes that have potent proinflammatory effects in a number of diseases. Studies have shown that eosinophils exhibit immunoregulation and antiviral activity. Further, both human and murine eosinophils synthesize NO through inducible NO synthase, which directly shows antiviral, effects on RSV and parainfluenza virus. Studies have shown that preclinical trials demonstrated antiviral activity for eosinophils. Mulmina® showed significant reduction in the elevated levels of leukocytes and eosinophil.4
In case of allergic inflammation, Histamine plays the role of a key mediator. Mulmina® showed the anti-allergic activity by inhibiting the deleterious effect of histamine by blocking its release from cells and inhibiting the airway smooth muscle contraction and also by reducing inflammatory cytokines and oxidative stress.
The symptoms of allergic inflammation (AI) also PRODUCED BY other inflammatory mediators WHICH ARE released primarily by mast cells (MCs) and basophils activated by antigen–IgE interactions.
Weller and Maurer studied and reported that desloratadine inhibits activation of human skin MCs. The inhibitory effect was the strongest when stimulated with anti-IgE (50.7% inhibition; P<0.05, then by substance P (48.0% inhibition; P<0.005), and then by Ca-ionophore (26.7% inhibition; P<0.01). Mulmina® treatment exhibited mast cell stabilizing property.
The above studies show that Mulmina® was safe and effective. It exhibited stabilization ofmast cells which proved its anti-allergic activity, reduced elevated levels of leucocytes and eosinophil, inhibited smooth muscle contraction o the airway in allergic condition, provided protection against bronchoconstriction induced by histamine. All these properties make it a perfect supplement for boosting immunity and help as a preventive measure against viral infections such a COVID-19.
- Han P, Gu J-Q, Li L-S, Wang X-Y, Wang H-T, Wang Y, et al. The Association Between Intestinal Bacteria and Allergic Diseases—Cause or Consequence? Frontiers in Cellular and Infection Microbiology. 2021;11(284).
- Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-54.
- Mulmina, Scientific updates,Update-1, 1-64.
- Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020;146(1):1-7.
- Levi-Schaffer F, Eliashar R. Mast cell stabilizing properties of antihistamines. The Journal of investigative dermatology. 2009;129(11):2549-51.
- Weller K, Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. The Journal of investigative dermatology. 2009;129(11):2723-6.